Trade Summary

3 days ago, Bodenstedt Matthias, serving as CFO at Moonlake Immunotherapeutics (MLTX), sold 13,653 shares at $20.02 per share, for a total transaction value of $273,333.00. Following this transaction, Bodenstedt Matthias now holds 1,172,431 shares of MLTX.

This sale represents a 1.00% decrease in Bodenstedt Matthias's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, May 11, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, May 13, 2026, 2 days after the trade was made.

Moonlake Immunotherapeutics operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.